Supplemental data

Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust anti-tumor immune responses and enhances immune checkpoint blockade

Won Suk Lee, Dong Sung Kim, Jeong Hun Kim, Yoonki Heo, Hannah Yang, Eun-Jin Go, Jin Hyoung Kim, Seung Joon Lee, Byung Cheol Ahn, Jung Sun Yum, Hong Jae Chon, and Chan Kim
Supplemental Figure 1. LP-based therapy did not show gross toxicities.

In both MC38 colon cancer (A) and B16F10 melanoma (B) models, body weight was not changed after LP-based therapy compared with control and splenomegaly was not observed in all mice. Scale bars, 10 mm.